Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1477)

VOLUNTARY ANNOUNCEMENT
NMPA APPROVAL FOR LOCALIZED PRODUCTION OF FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business developments of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that the fluocinolone acetonide intravitreal implant of the Group (the "**Product**") has recently been approved by the National Medical Products Administration (the "**NMPA**") of the People's Republic of China (the "**PRC**") for manufacture in the Chinese Mainland.

The Product was submitted for registration as a Class 4 chemical drug and has been included in the priority review and approval procedure for drug marketing authorization of the NMPA; its manufacturing technology was acquired by the Group through technology transfer, and the process transfer and process validation have been completed.

The Group's core product, OT-401 (generic name: fluocinolone acetonide intravitreal implant, "**Youshiying**"), has been commercialized in the PRC and, for its approved indication of chronic non-infectious uveitis affecting the posterior segment, has been included in the National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-related Injury Insurance. Since its launch, Youshiying has addressed the clinical needs of a substantial number of patients. To date, Youshiying supplied in the PRC market has been manufactured at the overseas manufacturing site specified in its import drug registration certificate and imported into the PRC.

The approval enables localized production of the Product, providing the Group with a supplementary source of supply to the PRC market in addition to the existing overseas manufacturing and importation. The Board believes that this arrangement will bring the following benefits:

(i) **Enhanced supply resilience.** An additional domestic source of supply reduces reliance on a single manufacturing site and on cross-border logistics, and safeguards stable supply for long-term patient treatment.

(ii) **Improved accessibility.** A shorter supply chain and delivery lead time, together with the Group's nationwide commercial network, will benefit patients in more regions.

(iii) **Enhanced industrial capability.** The Group has established the manufacturing process and quality control capabilities for intraocular implants, which have potential for application in other ophthalmic implant and sustained-release products, and is able to optimize the cost structure of the Product.

This announcement contains certain forward-looking statements relating to, among other things, the commercial manufacturing plan for the Product and the expected benefits. Such statements are subject to a number of risks and uncertainties, and actual results may differ materially from those stated in such forward-looking statements. The Group undertakes no obligation to update any forward-looking statement.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, October 27, 2026

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Ms. Beibei ZHUANG, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.